{"id":2999,"date":"1996-01-09T16:52:52","date_gmt":"1996-01-09T15:52:52","guid":{"rendered":"https:\/\/www.rcts.fr\/uncategorized\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer"},"modified":"1996-01-09T16:52:52","modified_gmt":"1996-01-09T15:52:52","slug":"taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/","title":{"rendered":"Taxol \u00ae (paclitaxel) 225mg\/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer"},"content":{"rendered":"<table width=\"538\">\n<tbody>\n<tr>\n<td width=\"292\">Proceedings of the American Society of Clinical Oncology 1996<\/td>\n<td width=\"246\">Bonneterre J, Tubiana-Hulin M, Chollet Ph, Chevallier B, Fumoleau P, Kerbrat P, Vi\u00e9 B, Khayat D, Tubiana N, Lejeune C, Soler-Michel P, Soares JA, Pellae-Cosset B, Chazard M.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Proceedings of the American Society of Clinical Oncology 1996 Bonneterre J, Tubiana-Hulin M, Chollet Ph, Chevallier B, Fumoleau P, Kerbrat P, Vi\u00e9 B, Khayat D, Tubiana N, Lejeune C, Soler-Michel P, Soares JA, Pellae-Cosset B, Chazard M.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false},"categories":[63],"class_list":["post-2999","post","type-post","status-publish","format-standard","hentry","category-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Taxol \u00ae (paclitaxel) 225mg\/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer - RCTs<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Taxol \u00ae (paclitaxel) 225mg\/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer - RCTs\" \/>\n<meta property=\"og:description\" content=\"Proceedings of the American Society of Clinical Oncology 1996 Bonneterre J, Tubiana-Hulin M, Chollet Ph, Chevallier B, Fumoleau P, Kerbrat P, Vi\u00e9 B, Khayat D, Tubiana N, Lejeune C, Soler-Michel P, Soares JA, Pellae-Cosset B, Chazard M.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"RCTs\" \/>\n<meta property=\"article:published_time\" content=\"1996-01-09T15:52:52+00:00\" \/>\n<meta name=\"author\" content=\"Didier Not\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Didier Not\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\\\/\"},\"author\":{\"name\":\"Didier Not\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\"},\"headline\":\"Taxol \u00ae (paclitaxel) 225mg\\\/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer\",\"datePublished\":\"1996-01-09T15:52:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\\\/\"},\"wordCount\":56,\"commentCount\":0,\"publisher\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#organization\"},\"articleSection\":[\"Oncology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\\\/\",\"name\":\"Taxol \u00ae (paclitaxel) 225mg\\\/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer - RCTs\",\"isPartOf\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#website\"},\"datePublished\":\"1996-01-09T15:52:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rcts.fr\\\/en\\\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Taxol \u00ae (paclitaxel) 225mg\\\/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#website\",\"url\":\"http:\\\/\\\/www.rcts.fr\\\/\",\"name\":\"RCTs\",\"description\":\"Description\",\"publisher\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\\\/\\\/www.rcts.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#organization\",\"name\":\"RCTs\",\"url\":\"http:\\\/\\\/www.rcts.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"contentUrl\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"width\":163,\"height\":47,\"caption\":\"RCTs\"},\"image\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\",\"name\":\"Didier Not\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"caption\":\"Didier Not\"},\"url\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/author\\\/dnorcts-fr\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Taxol \u00ae (paclitaxel) 225mg\/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer - RCTs","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Taxol \u00ae (paclitaxel) 225mg\/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer - RCTs","og_description":"Proceedings of the American Society of Clinical Oncology 1996 Bonneterre J, Tubiana-Hulin M, Chollet Ph, Chevallier B, Fumoleau P, Kerbrat P, Vi\u00e9 B, Khayat D, Tubiana N, Lejeune C, Soler-Michel P, Soares JA, Pellae-Cosset B, Chazard M.","og_url":"https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/","og_site_name":"RCTs","article_published_time":"1996-01-09T15:52:52+00:00","author":"Didier Not","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Didier Not"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/"},"author":{"name":"Didier Not","@id":"http:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5"},"headline":"Taxol \u00ae (paclitaxel) 225mg\/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer","datePublished":"1996-01-09T15:52:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/"},"wordCount":56,"commentCount":0,"publisher":{"@id":"http:\/\/www.rcts.fr\/#organization"},"articleSection":["Oncology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/","url":"https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/","name":"Taxol \u00ae (paclitaxel) 225mg\/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer - RCTs","isPartOf":{"@id":"http:\/\/www.rcts.fr\/#website"},"datePublished":"1996-01-09T15:52:52+00:00","breadcrumb":{"@id":"https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.rcts.fr\/en\/taxol-paclitaxel-225mg-m2-by-3-hour-infusion-without-g-csf-as-a-first-line-therapy-in-patients-with-metastatic-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/www.rcts.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Taxol \u00ae (paclitaxel) 225mg\/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer"}]},{"@type":"WebSite","@id":"http:\/\/www.rcts.fr\/#website","url":"http:\/\/www.rcts.fr\/","name":"RCTs","description":"Description","publisher":{"@id":"http:\/\/www.rcts.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/www.rcts.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"http:\/\/www.rcts.fr\/#organization","name":"RCTs","url":"http:\/\/www.rcts.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/www.rcts.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","contentUrl":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","width":163,"height":47,"caption":"RCTs"},"image":{"@id":"http:\/\/www.rcts.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"http:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5","name":"Didier Not","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","caption":"Didier Not"},"url":"https:\/\/www.rcts.fr\/en\/author\/dnorcts-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/comments?post=2999"}],"version-history":[{"count":0,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2999\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/media?parent=2999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/categories?post=2999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}